Abstract 4505
Background
Metastatic primary adrenal tumors include those of cortical origin (ACC) and medullary origin (malignant pheochromocytoma/paraganglioma (MP)). Given the rarity of these cancers, standard treatment options are limited, and outcomes are often dismal. In a previous study of single agent pembrolizumab, the proportion of patients with ACC and MP found to have disease control at 6 months defined as stable disease or better using RECIST v1.1 was greater than 25% of patients. Given the FDA approval of nivolumab and ipilimumab (N+I) with both melanoma and metastatic renal cell carcinoma with enhanced overall response rates (ORR) compared to single agent nivolumab in these diseases we sought to study this combination in rare genitourinary tumors (GU). NCT03333616 is a multicenter, single arm, phase II study of N+I in rare GU tumors including cohorts for ACC and MP, urothelial cancer pure variants, and other rare GU tumors. Herein, we report the preliminary results of the fully accrued adrenal cohort.
Methods
Eligible patients with ACC or MP required measurable disease as defined by RECIST v1.1, an ECOG performance status of 0-2, and may have received any line of prior therapy excluding prior immunotherapy. Hormonal therapy for hormonally active tumors was allowed. Patients underwent a baseline biopsy and received treatment with N 3 mg/kg and I 1 mg/kg intravenously every 3 weeks for 4 cycles with continued maintenance of N 480 mg IV every 4 weeks. The primary endpoint is overall response rate (ORR) by RECIST 1.1. Accrual is complete with 19 patients enrolled into ACC cohort.
Results
The ORR will be reported with 80% CI with all patients completing at least one scan. Secondary endpoints of immune-related toxicity rates will also be presented.
Conclusions
These results will inform the role of immunotherapy combinations in the management of advanced ACC.
Clinical trial identification
NCT03333616.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
BMS.
Disclosure
M.T. Campbell: Honoraria (self): Pfizer; Honoraria (self): Genentech; Honoraria (self): Apricity Health LLC; Advisory / Consultancy: EMD Serono, Inc; Advisory / Consultancy: Genentech, Inc. A.Y. Shah: Honoraria (self): Eisai; Honoraria (self): Oncology Information Group; Honoraria (self): Roche Pharmaceuticals; Research grant / Funding (institution): Eisai; Research grant / Funding (institution): BMS; Research grant / Funding (institution): EMD Serono. M.A. Habra: Research grant / Funding (self): Exelixis; Research grant / Funding (self): HRA Pharma. B.A. McGregor: Honoraria (self), Advisory / Consultancy: Astellas; Honoraria (self), Advisory / Consultancy: Seattle Genetics; Honoraria (self), Advisory / Consultancy: Nektar; Honoraria (self), Advisory / Consultancy: Exiles; Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy: Genentech; Honoraria (self), Advisory / Consultancy: Janssen; Honoraria (self), Advisory / Consultancy: EMD Serono; Honoraria (self), Advisory / Consultancy: Decibel; Research grant / Funding (institution): BMS. M.A. Bilen: Advisory / Consultancy: Exelixis; Advisory / Consultancy: Nektar; Advisory / Consultancy: GenomicHealth; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Sanofi; Research grant / Funding (institution): Bayer; Research grant / Funding (self): Bristol-Myers Squibb; Research grant / Funding (self): Genentech/Roche; Research grant / Funding (self): Incyte; Research grant / Funding (self): Nektar; Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): Tricon Pharmaceuticals; Research grant / Funding (self): Peleton; Research grant / Funding (self): Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
2344 - Lung Cancer in Europe: strengthening policy responses to address unmet needs
Presenter: Mary Bussell
Session: Poster Display session 3
Resources:
Abstract
1359 - Curative treatment timelines for breast, colorectal, lung and prostate cancer: Implications for medical leave coverage
Presenter: Selina Wong
Session: Poster Display session 3
Resources:
Abstract
4433 - Acute Diagnostic Oncology Clinic: A Unique Primary Care-Oncology Service
Presenter: Abhijit Gill
Session: Poster Display session 3
Resources:
Abstract
3506 - THE NEW MUTATIONAL MODEL IN ONCOLOGY. What changes in welfare, clinical practice, research, and regulatory procedures
Presenter: Nicola Normanno
Session: Poster Display session 3
Resources:
Abstract
3350 - Selection of a set of quality indicators (QI) for oncological clinical pathway
Presenter: Aude Fourcade
Session: Poster Display session 3
Resources:
Abstract
4400 - Sustainable drug prices at market launch: policy proposals and their empirical evidence
Presenter: Nora Fanzen
Session: Poster Display session 3
Resources:
Abstract
4118 - Impact of financial considerations on French physicians’ prescription choices for advanced non-small cell lung cancer (NSCLC)
Presenter: Nathalie Olympios
Session: Poster Display session 3
Resources:
Abstract
1340 - The direct medical cost of breast cancer in a Belgian hospital
Presenter: Hannan Lemhouer
Session: Poster Display session 3
Resources:
Abstract
1863 - Does the healthcare system approaches cancer patients for using private services during diagnostic process?
Presenter: Karolina Osowiecka
Session: Poster Display session 3
Resources:
Abstract
2637 - Measuring financial toxicity of cancer in the Italian health care system: initial results of the patient reported outcome for Fighting Financial Toxicity of cancer project (proFFiT).
Presenter: Silvia Riva
Session: Poster Display session 3
Resources:
Abstract